Spiration Valve System (SVS)
Gyrus Acmi, Inc. · Decision date May 7, 2026
What did the FDA decide?
FDA records P180007/S015 as a supplement to PMA P180007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 7, 2026.
FDA approval order statement
The firm is submitting this 30-Day Notice of a change in the verification and validation process of the Water Treatment System. The firm is adding endotoxin testing for the water samples and related process modifications to the manufacturing work instruction.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Anesthesiology
- Decision date
- May 7, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180007/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Gyrus Acmi, Inc.
- Product code
- NJK
- Decision code
- OK30
- Decision date
- May 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Valve, pulmonary.
- Applicant
- Gyrus Acmi, Inc.
- Product code
- NJK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180007/S015 received
Application receipt date recorded by FDA.
P180007/S015 · FDA decision
30-Day Notice
P180007/S016 · Related supplement
Spiration Valve System
Timeline entries are records held by MedtechLedger for P180007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Spiration Valve SystemP180007/S016 | Gyrus Acmi, Inc. | PMA supplement | Aug 20, 2026 | FDA |
Explore the linked device profile
Other records with product code NJK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Zephyr Endobronchial Valve SystemP180002/S032 | Pulmonx Corporation | PMA supplement | Sep 11, 2026 | FDA |
Zephyr Endobronchial Valve (EBV) SystemP180002/S031 | Pulmonx Corporation | PMA supplement | Jun 17, 2026 | FDA |
Zephyr Endobronchial Valve (EBV) SystemP180002/S030 | Pulmonx Corporation | PMA supplement | Mar 17, 2026 | FDA |
| Pulmonx Corporation | PMA approval | Jun 29, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Gyrus Acmi, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6675 185th Ave. NE, Redmond, WA, 98052
Sources and methodology
- Original FDA record: P180007/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records